Table 3.
Tocilizumab compared to control cohort based on propensity-weighteda models for quality of life patient-reported outcomes after adjusting for baseline values and aGVHD (grades II–IV).
| Assessment | Day 28 | Day 100 | Day 180 | |||
|---|---|---|---|---|---|---|
| Estimate (95% CI) | P value | Estimate (95% CI) | P value | Estimate (95% CI) | P value | |
| Depression | 4.73 (0.64, 8.81) | 0.02 | 1.54 (−2.81, 5.88) | 0.49 | 4.41 (−0.59, 9.40) | 0.08 |
| Anxiety | 1.64 (−0.16, 3.44) | 0.07 | 2.82 (0.86, 4.78) | 0.005 | 1.76 (−0.48, 4.00) | 0.12 |
| Fatigue, intensity | 0.36 (−0.41, 1.13) | 0.36 | 0.18 (−0.66, 1.01) | 0.68 | 0.89 (−0.05, 1.82) | 0.06 |
| Fatigue, duration | 1.13 (−0.56, 2.83) | 0.19 | 1.11 (−0.70, 2.93) | 0.23 | 1.22 (−0.85, 3.30) | 0.25 |
| Fatigue, interference | −0.31 (−1.16, 0.54) | 0.47 | −0.27 (−1.18, 0.64) | 0.56 | −0.37 (−1.41, 0.67) | 0.48 |
| Pain, intensity | 1.22 (0.49, 1.96) | 0.001 | 0.27 (−0.53, 1.07) | 0.50 | 0.98 (0.07, 1.88) | 0.04 |
| Pain, interference | 0.11 (−0.78, 0.99) | 0.81 | −0.15 (−1.13, 0.82) | 0.75 | 0.08 (−1.02, 1.19) | 0.88 |
| Sleep | 1.32 (−0.30, 2.94) | 0.11 | 1.47 (−0.23, 3.17) | 0.09 | 2.46 (0.54, 4.38) | 0.01 |
aPropensity scores were obtained using a logistic regression model with age, sex, BMI, CMV status, conditioning regimen, and donor type as predictors of study group.